Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Aytu Biopharma (AYTU) over the last 15 years, with Sep 2025 value amounting to -$1.6 million.

  • Aytu Biopharma's Change in Accured Expenses rose 67.06% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 145.34%. This contributed to the annual value of $886,000 for FY2025, which is 109.67% up from last year.
  • Per Aytu Biopharma's latest filing, its Change in Accured Expenses stood at -$1.6 million for Q3 2025, which was up 46.54% from -$3.1 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Accured Expenses peaked at $8.0 million during Q1 2023, and registered a low of -$14.5 million during Q2 2022.
  • For the 3-year period, Aytu Biopharma's Change in Accured Expenses averaged around -$512,545, with its median value being -$1.6 million (2025).
  • As far as peak fluctuations go, Aytu Biopharma's Change in Accured Expenses tumbled by 574.67% in 2022, and later spiked by 879.88% in 2025.
  • Aytu Biopharma's Change in Accured Expenses (Quarterly) stood at -$3.9 million in 2021, then spiked by 162.73% to $2.5 million in 2022, then crashed by 48.52% to $1.3 million in 2023, then surged by 474.23% to $7.3 million in 2024, then skyrocketed by 67.06% to -$1.6 million in 2025.
  • Its Change in Accured Expenses stands at -$1.6 million for Q3 2025, versus -$3.1 million for Q2 2025 and $1.6 million for Q1 2025.